How to Create a Manual Lymphatic Drainage Informed Consent Form for Lymphatic Drainage Specialists (with Free Template)
This guide walks a manual lymphatic drainage specialist through the ten substantive steps of building a client informed consent and intake form that holds up under state-board scrutiny, survives the higher-risk post-cosmetic-surgery and lymphedema-management caseloads, and produces a tamper-evident audit trail. Each step is one paragraph of working guidance. Estimated time end-to-end: 45 minutes from blank document to signed PDF when using an AI form builder. Formfy is the AI form builder MLD practitioners use; the same builder produces the consent and intake, captures the e-signature, and exports an audit trail aligned with HIPAA and surgeon-release documentation requirements.
Before you start, gather six pieces of information: (1) the practitioner credential summary (state license, MLD training method and school, LANA-CLT status if applicable), (2) the scope of services offered (basic MLD, CDT, post-cosmetic-surgery, lymphedema management, oncology), (3) the surgeon-release documentation template, (4) the contraindications screening list aligned with the patient population the practice serves, (5) the HIPAA posture if billing insurance or operating under physician supervision, and (6) the BAA inventory of vendors that handle PHI. With those six inputs, the substantive drafting takes under 45 minutes.
Step 1: Identify the scope (basic MLD vs Complete Decongestive Therapy)
Begin by stating exactly what work the practice delivers. Manual Lymphatic Drainage (MLD) at the basic level is a specific manual technique to support lymph flow; basic MLD can be performed by a Licensed Massage Therapist with documented MLD training. Complete Decongestive Therapy (CDT) is a four-component clinical protocol (MLD plus compression bandaging plus exercise plus skin care) used for lymphedema management; CDT typically requires Lymphology Association of North America Certified Lymphedema Therapist (LANA-CLT) credentialing, which has medical-professional prerequisites (PT, OT, MD, DO, DC, RN, MT, or LMT depending on the program). State the scope clearly on the consent so the client understands which protocol the practice offers. Misrepresenting basic MLD as CDT, or implying lymphedema-management capability without the credential, exposes the practitioner to state-board complaints and patient harm.
Step 2: Reference the method (Vodder, Foldi, Casley-Smith, Klose) acknowledged in training
MLD is taught in four primary recognized methods, and the practitioner training method should be acknowledged on the consent. The Vodder Method (developed by Emil and Estrid Vodder in the 1930s) is the original MLD technique. The Foldi Method (developed by Michael and Ethel Foldi) is the European clinical-medicine standard, particularly for CDT. The Casley-Smith Method (developed by Judith and John Casley-Smith) is widely taught in Australia and globally with research backing. The Klose Method (developed by Guenter Klose) is widely used in the United States, particularly for post-cosmetic-surgery and oncology contexts. State the practitioner training method, the school, and the documented hours so the client understands the technique foundation. Method acknowledgment supports informed consumer choice and aligns with truth-in-advertising standards.
Step 3: Require surgeon release for post-cosmetic-surgery MLD (BBL, lipo, abdominoplasty)
Post-cosmetic-surgery MLD is one of the most-requested services in the modern MLD practice (BBL, liposuction, abdominoplasty, mommy makeover, breast surgery). State an explicit surgeon-released requirement on the consent. The practice does not provide MLD for any post-cosmetic-surgery client without documented release from the operating surgeon stating: the patient is cleared for soft-tissue work in specified areas, the surgical sites are healed sufficiently to tolerate manual contact, the patient has met the surgeons benchmarks for activity and for compression-garment use, drains have been removed (where applicable), and there are no remaining contraindications such as open incisions, infections, or anticoagulant therapy. Capture the release in the patient record before the first session and re-confirm before any session that follows new symptoms. Most post-cosmetic-surgery MLD malpractice claims trace to sessions delivered before adequate clearance.
Step 4: Distinguish lymphedema scope from cosmetic edema reduction
Lymphedema is a clinical condition caused by lymphatic system dysfunction (often post-surgical, post-radiation, or congenital) and is managed with CDT under medical supervision. Cosmetic edema reduction refers to the temporary swelling that follows cosmetic surgery and resolves naturally as healing progresses; basic MLD may support comfort and recovery in this window. State the scope clearly on the consent so the client understands the difference. Practitioners offering only basic MLD must not market or describe their work as lymphedema management. Practitioners offering CDT for lymphedema must hold the LANA-CLT or equivalent credential and typically work under physician supervision. Misrepresenting cosmetic-edema work as lymphedema management is a leading source of state-board complaints and FTC concerns.
Step 5: Acknowledge ISL lymphedema staging where relevant
The International Society of Lymphology (ISL) publishes a recognized lymphedema staging system: Stage 0 (latent, subclinical), Stage I (early reversible), Stage II (spontaneously irreversible), and Stage III (lymphostatic elephantiasis). Practitioners working with lymphedema patients should acknowledge ISL staging in the consent and intake so the medical-professional context is clear. Document the patients staged condition (per the referring physician) on the intake. Basic MLD practitioners typically do not stage patients themselves; staging is a clinical determination by the treating physician, oncologist, or lymphedema specialist. Reference ISL staging on the consent only when the practice actually serves staged-lymphedema patients under physician supervision; for cosmetic-edema clients, the staging language is irrelevant and should be omitted to avoid implying clinical scope.
Step 6: Screen contraindications (acute infection, CHF, DVT, active malignancy without medical clearance)
MLD has a defined contraindications list that requires careful screening. Absolute contraindications: acute infection (cellulitis, lymphangitis, untreated bacterial infections), uncontrolled congestive heart failure (CHF) because increased lymph return can overload the heart, deep vein thrombosis (DVT) within twelve months because lymphatic stimulation can dislodge clots, active malignancy without oncologist clearance because of theoretical concerns about cancer cell mobilization, acute renal failure, and pulmonary embolism history within twelve months. Require physician clearance before any session for: post-radiation tissue, recent surgery within twelve weeks unless surgeon-released, current anticoagulant therapy, hypothyroidism, and asthma. Screen on the intake form, document the screen in the record, and route any positive answer to a clearance flow. Re-confirm before any session that follows new symptoms. Document everything.
Step 7: State HIPAA compliance posture for medical-billing scenarios (45 CFR 164.502)
HIPAA applies when the MLD practice operates as a covered entity under 45 CFR 160.103. Most basic MLD practitioners are not HIPAA covered because they do not bill insurance and do not transmit electronic health information in HIPAA-defined standard transactions. CDT-credentialed practitioners working under physician supervision, MLD specialists embedded in medical-billing practices, and practitioners accepting HSA or FSA cards processed electronically may be covered. State the HIPAA posture explicitly on the consent. When covered, reference 45 CFR 164.502 (Privacy Rule core uses and disclosures), provide the patient with a current Notice of Privacy Practices, and capture written acknowledgment of receipt. Even when not HIPAA-covered, applying HIPAA-equivalent privacy practices is the conservative default for clinical-MLD settings, and many state medical-records laws apply regardless.
Step 8: Define compression bandaging scope (CLT credential typically required)
Compression bandaging is a CDT component that typically requires LANA-CLT or equivalent credentialing because incorrect bandaging can worsen lymphedema, restrict circulation, or cause skin breakdown. Basic MLD practitioners without CLT credentialing should not provide compression bandaging as a stand-alone service. Compression-garment fitting (off-the-shelf or custom-fitted) is a related but distinct scope; some MLD practitioners with appropriate training fit compression garments under physician orders, while others refer to a certified fitter or DME supplier. State the practice scope clearly on the consent: which compression services are offered, which are not, and the referral path for services outside scope. Patients with lymphedema typically require compression as a core therapy element; misrepresenting compression scope leads to clinical and regulatory issues.
Step 9: Address wound contraindications and skin-integrity screening
Wounds and skin-integrity issues are absolute contraindications to MLD until cleared. Open wounds, surgical incisions before healing benchmarks, infected wounds, post-radiation skin breakdown, suspected malignant skin lesions, severe eczema or psoriasis flares, recent burns, and contagious skin conditions all contraindicate MLD. Screen on the intake form and visually inspect at each session before initiating manual contact. Document the inspection in the session record. State the wound contraindication clearly on the consent so the client understands the practice will not proceed when wounds are present. For post-cosmetic-surgery clients with healing incisions, the surgeon-released requirement (Step 3) addresses the timing question; the visual inspection at each session validates that the surgeon-released benchmark continues to hold. Document everything; wound-related complications drive a substantial share of MLD malpractice claims.
Step 10: Sign and store securely with a tamper-evident audit trail
Use an e-signature workflow that produces a tamper-evident audit trail with timestamp, IP address, and consent to electronic records. The federal Electronic Signatures in Global and National Commerce Act (ESIGN Act, 15 USC 7001) and the Uniform Electronic Transactions Act (UETA) adopted in 49 states make e-signed MLD consent forms legally equivalent to wet-ink. Store the signed consent in a system that lets the practice retrieve it on 24-hour notice if a state board, malpractice carrier, or HIPAA auditor asks. Federal courts and state boards have broadly accepted ESIGN-compliant audit trails. Standard retention for MLD records is at least seven years from the last service date; HIPAA-covered practices must retain Privacy Rule documentation for six years from creation under 45 CFR 164.530(j). Encrypt at rest, restrict access by role, and index by patient name and service date.
Free template and downloadable PDF
Formfy ships a manual lymphatic drainage informed consent template that maps one-to-one to the ten steps in this guide. The template is editable in the AI form builder: describe the practice in plain English and the builder returns a delivery-ready consent and intake form with the e-signature block, the contraindications screening, the surgeon-release documentation gate for post-cosmetic-surgery clients, the method-acknowledgment paragraph, and an optional session-deposit payment field. The PDF version is generated automatically when the client signs and stored alongside the audit trail.
See also: /faq/lymphatic-drainage-specialists-mld-informed-consent for the FAQ companion hub.
Related resources
Build an MLD consent and intake in 30 seconds
Free 15-day Formfy trial. No credit card. Submission-based pricing.
Start your free trialLast verified: 2026-04-25. This page is informational; it is not legal advice. MLD practitioners should review state-specific licensing rules, post-cosmetic-surgery scope with surgeon counsel, and lymphedema-management scope with a LANA-CLT credentialed reviewer where applicable.